Homologous recombination-IN-1

Cat. No.:	HY-148183
CAS No.:	391889-85-3
Molecular Formula:	$C_{28}H_{24}ClN_3O_3$
Molecular Weight:	485.96
Target:	RAD51
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (102.89 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.0578 mL	10.2889 mL	20.5778 mL
	5 mM	0.4116 mL	2.0578 mL	4.1156 mL
	10 mM	0.2058 mL	1.0289 mL	2.0578 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Homologous recombination-IN-1 is a novel RAD51-BRCA2 protein-protein interaction inhibitor (EC_{50}=19 μM). Homologous recombination-IN-1 can interfere with homologous recombination[1].

In Vitro

Homologous recombination-IN-1 (10-40 μM; 5 h) reduces cell homologous recombination in a dose-dependent manner[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	BxPC3 cells
Concentration:	10-40 μM
Incubation Time:	5 hours
Result:	Led to homologous recombination inhibition with an EC_{50} value of 18.4 μM.

REFERENCES

[1]. Bagnolini G, et al. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib. J Med Chem. 2020 Mar 12;63(5):2588-2619.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA